Free Trial

Fresh Tracks Therapeutics Q1 2023 Earnings Report

Fresh Tracks Therapeutics logo
$0.66 0.00 (0.00%)
As of 01:54 PM Eastern

Fresh Tracks Therapeutics EPS Results

Actual EPS
-$1.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Fresh Tracks Therapeutics Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Fresh Tracks Therapeutics Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Fresh Tracks Therapeutics Earnings Headlines

Do this Before Elon’s Reveal on January 29th
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
Fresh Tracks Therapeutics Inc (FRTX)
See More Fresh Tracks Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fresh Tracks Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fresh Tracks Therapeutics and other key companies, straight to your email.

About Fresh Tracks Therapeutics

Fresh Tracks Therapeutics (NASDAQ:FRTX) does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

View Fresh Tracks Therapeutics Profile

More Earnings Resources from MarketBeat